Path ID: DB09037_MESH_D002289_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| DB:DB09037 | Pembrolizumab | Drug |
| UniProt:Q15116 | Programmed cell death protein 1 | Protein |
| GO:0042098 | T cell proliferation | BiologicalProcess |
| GO:0042110 | T cell activation | BiologicalProcess |
| GO:0002424 | T cell mediated immune response to tumor cell | BiologicalProcess |
| MESH:D002289 | Non-small cell lung cancer (PD-L1 expression positive) | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Pembrolizumab | DECREASES ACTIVITY OF | Programmed Cell Death Protein 1 |
| Programmed Cell Death Protein 1 | NEGATIVELY REGULATES | T Cell Proliferation |
| Programmed Cell Death Protein 1 | NEGATIVELY REGULATES | T Cell Activation |
| T Cell Proliferation | POSITIVELY CORRELATED WITH | T Cell Mediated Immune Response To Tumor Cell |
| T Cell Activation | POSITIVELY CORRELATED WITH | T Cell Mediated Immune Response To Tumor Cell |
| T Cell Mediated Immune Response To Tumor Cell | NEGATIVELY CORRELATED WITH | Non-Small Cell Lung Cancer (Pd-L1 Expression Positive) |
Comment: Pembrolizumab is indicated for first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression [(Tumor Proportion Score (TPS) ≥50%)] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations
Reference: